Prognostication of Brain-Metastasized Patients Receiving Subsequent Systemic Therapy: A Single-Center Long-Term Follow-Up
Background. Survival of patients with brain metastases (BMs) is poor. It has become clear that targeted therapy has an effect on BMs and patient’ prognosis. The question remains which patients benefit from additional systemic therapy. This assumption was evaluated in a large single-center cohort. Me...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2025-01-01
|
| Series: | Current Oncology |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1718-7729/32/2/74 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850080828740075520 |
|---|---|
| author | Tijl Vermassen Charlotte Van Parijs Stijn De Keukeleire Katrien Vandecasteele Sylvie Rottey |
| author_facet | Tijl Vermassen Charlotte Van Parijs Stijn De Keukeleire Katrien Vandecasteele Sylvie Rottey |
| author_sort | Tijl Vermassen |
| collection | DOAJ |
| description | Background. Survival of patients with brain metastases (BMs) is poor. It has become clear that targeted therapy has an effect on BMs and patient’ prognosis. The question remains which patients benefit from additional systemic therapy. This assumption was evaluated in a large single-center cohort. Methods. Patients consecutively planned to undergo local radiotherapy for their BMs in 2006–2017 were selected (<i>n</i> = 200). Prognosis, using CERENAL, disease-specific graded prognostic assessment (DS-GPA), and Radiation Therapy Oncology Group recursive partitioning analysis (RTOG RPA), was evaluated. Results. Ninety-three (46.5%) patients received at least one additional line of systemic therapy subsequent to the diagnosis of their BMs. The median overall survival (OS) was 6.3 months. Having received subsequent systemic therapy resulted in a more favorable OS (10.4 versus 3.9 months). Interestingly, using dichotomized scores, CERENAL showed prognostic properties in all patients for disease-specific survival on multivariate analysis, whereas RTOG RPA and DS-GPA were not withheld in the model. Lastly, only having a favorable DS-GPA resulted in prolonged progression-free survival for first systemic therapy following BM diagnosis. Conclusions. Receiving subsequent systemic therapy has a profound influence on outcome in patients with BMs, indicating the effect of systemic therapy on BMs. Use of the CERENAL brain prognostic score shows potential for further prognostication of patients with more favorable outcomes. |
| format | Article |
| id | doaj-art-d791f06f3afd4b73ac13640b3c91c76e |
| institution | DOAJ |
| issn | 1198-0052 1718-7729 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Current Oncology |
| spelling | doaj-art-d791f06f3afd4b73ac13640b3c91c76e2025-08-20T02:44:52ZengMDPI AGCurrent Oncology1198-00521718-77292025-01-013227410.3390/curroncol32020074Prognostication of Brain-Metastasized Patients Receiving Subsequent Systemic Therapy: A Single-Center Long-Term Follow-UpTijl Vermassen0Charlotte Van Parijs1Stijn De Keukeleire2Katrien Vandecasteele3Sylvie Rottey4Department Medical Oncology, Ghent University Hospital, 9000 Ghent, BelgiumDepartment Medical Oncology, Ghent University Hospital, 9000 Ghent, BelgiumDepartment Medical Oncology, Ghent University Hospital, 9000 Ghent, BelgiumCancer Research Institute Ghent, 9000 Ghent, BelgiumDepartment Medical Oncology, Ghent University Hospital, 9000 Ghent, BelgiumBackground. Survival of patients with brain metastases (BMs) is poor. It has become clear that targeted therapy has an effect on BMs and patient’ prognosis. The question remains which patients benefit from additional systemic therapy. This assumption was evaluated in a large single-center cohort. Methods. Patients consecutively planned to undergo local radiotherapy for their BMs in 2006–2017 were selected (<i>n</i> = 200). Prognosis, using CERENAL, disease-specific graded prognostic assessment (DS-GPA), and Radiation Therapy Oncology Group recursive partitioning analysis (RTOG RPA), was evaluated. Results. Ninety-three (46.5%) patients received at least one additional line of systemic therapy subsequent to the diagnosis of their BMs. The median overall survival (OS) was 6.3 months. Having received subsequent systemic therapy resulted in a more favorable OS (10.4 versus 3.9 months). Interestingly, using dichotomized scores, CERENAL showed prognostic properties in all patients for disease-specific survival on multivariate analysis, whereas RTOG RPA and DS-GPA were not withheld in the model. Lastly, only having a favorable DS-GPA resulted in prolonged progression-free survival for first systemic therapy following BM diagnosis. Conclusions. Receiving subsequent systemic therapy has a profound influence on outcome in patients with BMs, indicating the effect of systemic therapy on BMs. Use of the CERENAL brain prognostic score shows potential for further prognostication of patients with more favorable outcomes.https://www.mdpi.com/1718-7729/32/2/74brain metastasestargeted therapysurvival outcomeprognosisretrospective analysis |
| spellingShingle | Tijl Vermassen Charlotte Van Parijs Stijn De Keukeleire Katrien Vandecasteele Sylvie Rottey Prognostication of Brain-Metastasized Patients Receiving Subsequent Systemic Therapy: A Single-Center Long-Term Follow-Up Current Oncology brain metastases targeted therapy survival outcome prognosis retrospective analysis |
| title | Prognostication of Brain-Metastasized Patients Receiving Subsequent Systemic Therapy: A Single-Center Long-Term Follow-Up |
| title_full | Prognostication of Brain-Metastasized Patients Receiving Subsequent Systemic Therapy: A Single-Center Long-Term Follow-Up |
| title_fullStr | Prognostication of Brain-Metastasized Patients Receiving Subsequent Systemic Therapy: A Single-Center Long-Term Follow-Up |
| title_full_unstemmed | Prognostication of Brain-Metastasized Patients Receiving Subsequent Systemic Therapy: A Single-Center Long-Term Follow-Up |
| title_short | Prognostication of Brain-Metastasized Patients Receiving Subsequent Systemic Therapy: A Single-Center Long-Term Follow-Up |
| title_sort | prognostication of brain metastasized patients receiving subsequent systemic therapy a single center long term follow up |
| topic | brain metastases targeted therapy survival outcome prognosis retrospective analysis |
| url | https://www.mdpi.com/1718-7729/32/2/74 |
| work_keys_str_mv | AT tijlvermassen prognosticationofbrainmetastasizedpatientsreceivingsubsequentsystemictherapyasinglecenterlongtermfollowup AT charlottevanparijs prognosticationofbrainmetastasizedpatientsreceivingsubsequentsystemictherapyasinglecenterlongtermfollowup AT stijndekeukeleire prognosticationofbrainmetastasizedpatientsreceivingsubsequentsystemictherapyasinglecenterlongtermfollowup AT katrienvandecasteele prognosticationofbrainmetastasizedpatientsreceivingsubsequentsystemictherapyasinglecenterlongtermfollowup AT sylvierottey prognosticationofbrainmetastasizedpatientsreceivingsubsequentsystemictherapyasinglecenterlongtermfollowup |